Pfizer Inc. (PFE) Stock Price Prediction
Price target with bull & bear cases · AI-assisted, editorially reviewed · Re-evaluated every trading day
Our AI model’s current price target for PFE is $29.07 — 1.2% below the latest price of $29.43.
Target vs 52-Week Range
Bull Case vs Bear Case
Bull Case
The bull case for Pfizer rests on its diversified product portfolio and robust late-stage pipeline, which are expected to drive a return to growth by the end of the decade, mitigating the impact of patent cliffs. Recent positive developments include Phase 3 results for LITFULO in nonsegmental vitiligo and FDA approval for expanded use of the breast-cancer treatment Tukysa. Strategic collaborations, like the one with Enodia Therapeutics, and advancements in its oncology pipeline, as well as a promising GLP-1 drug candidate for weight management, are expected to fuel future growth. Furthermore, Pfizer's increasing integration of artificial intelligence in R&D could accelerate drug discovery and development.
Bear Case
The bear case highlights significant headwinds, including intense competitive pressure, vulnerability to generic and biosimilar competition, and potential revenue reductions due to loss of exclusivity, estimated at around $1.1 billion. Key products such as Prevnar, Comirnaty, and Paxlovid are experiencing softer sales estimates, compounded by declining vaccination rates and other market pressures. Financial concerns include the company's substantial debt, limited investment flexibility, and recent downward revisions of profit estimates by analysts. The stock is perceived as overvalued by some intrinsic valuation models, and aggressive cost-cutting in R&D could jeopardize long-term innovation. Additionally, ongoing patent lawsuits and workforce reductions pose further risks.
Model-assessed risk level: Medium
Key Catalysts to Watch
Upcoming IDWeek 2026 presentations (October 21-24) on advancements in infectious diseases and vaccines.
Third Quarter 2026 Performance Report and conference call on November 3, 2026.
Potential global regulatory submission for LITFULO in adult vitiligo.
Progress and data readouts from its next-generation pediatric pneumococcal vaccine Phase 3 trial.
Further development and clinical trial results for its GLP-1 drug candidate for weight management.
Advancements and approvals within its oncology pipeline.
Technical Backdrop
RSI-14
68.2
50-Day MA
$27.90
200-Day MA
$26.22
From 52-Wk High
0.0%
Full momentum breakdown: Is PFE overbought or oversold?
Model Notes
Pfizer Inc. (PFE) is a major pharmaceutical company with a diversified portfolio and a robust pipeline, actively pursuing new drug development in oncology, infectious diseases, and weight management. The stock has shown positive technical momentum recently, trading above key moving averages and reaching a new 52-week high. However, its fundamental health presents a mixed picture, with concerns regarding high debt levels, declining profitability year-over-year, and potential revenue hits from patent expirations. While the company offers a substantial dividend yield, its payout ratio is notably high. Analyst sentiment is varied, with an overall 'Moderate Buy' or 'Hold' consensus and a modest average price target upside.
PFE stock is currently in a rising trend channel in the medium term and has recently moved above its 50-day and 200-day simple moving averages, indicating positive momentum. It has been trading within a rectangle formation with support around $27.39-$27.40 and resistance at $28.56-$28.60. Several technical indicators, including MACD and moving averages, are signaling 'Buy', while the Relative Strength Index (RSI) is around 57.4, suggesting it is neither overbought nor oversold, though one source pegs it at 73.358, indicating a 'Buy' but leaning towards overbought territory. The stock recently hit a new 52-week high of $29.88, reflecting increased investor confidence.
Current Street Context
October 15, 2026The AI price target for Pfizer Inc. is $29.07. This target is very close to the current price, suggesting a relatively stable outlook based on the AI model. Pfizer's recent Q2 2026 earnings beat analyst EPS estimates, which has contributed to the stock's positive performance and its current position at a 52-week high. The next significant upcoming event for Pfizer is its earnings report, expected on November 3, 2026, before market open. Analysts will be closely observing this report for insights into the company's future revenue and EPS, with current forecasts anticipating a year-over-year decrease in EPS for the upcoming release. These targets are estimates and not guaranteed outcomes.
Frequently Asked Questions
What is the price target for PFE?
How is this forecast generated?
How accurate are stock price predictions?
Will PFE stock go up?
How often does the AI target change?
Methodology
The price target, bull and bear cases, and risk level are produced by an AI model that reviews PFE’s fundamentals, technical posture, current news flow, and analyst commentary via live web search. It re-evaluates every trading morning and evening; the street-context commentary refreshes each trading evening.
Targets are estimates, not guarantees. No model reliably predicts short-term prices — treat this page as a structured summary of what current information might justify, alongside the risks that could break the thesis.
Not Financial Advice
This page is for education and information only. Indicators are mechanical calculations, AI commentary can contain errors, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a qualified financial advisor. See our full disclaimer.
Keep Digging on PFE
Pfizer Inc. Overview
Price, chart, analysis & financials
PFE: Overbought or Oversold?
Updated daily
PFE: Why Is It Moving?
Updated daily
PFE: Undervalued or Overvalued?
Updated daily
Same question, Healthcare peers